ID   HCE-4
AC   CVCL_1271
SY   HCE4
DR   BTO; BTO:0005572
DR   CLO; CLO_0009932
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 869
DR   cancercelllines; CVCL_1271
DR   Cell_Model_Passport; SIDM00052
DR   ChEMBL-Cells; CHEMBL3308199
DR   ChEMBL-Targets; CHEMBL2366207
DR   Cosmic; 753559
DR   Cosmic; 923186
DR   Cosmic; 934539
DR   Cosmic; 1394519
DR   Cosmic-CLP; 753559
DR   DepMap; ACH-002243
DR   EGA; EGAS00001000978
DR   GDSC; 753559
DR   GEO; GSM482501
DR   GEO; GSM1669865
DR   IARC_TP53; 258
DR   LINCS_LDP; LCL-1563
DR   PharmacoDB; HCE4_514_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1271
DR   PubChem_Cell_line; CVCL_1271
DR   Wikidata; Q54881849
RX   PubMed=2263646;
RX   PubMed=2302677;
RX   PubMed=2415247;
RX   PubMed=2420787;
RX   PubMed=7972006;
RX   PubMed=20164919;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=30971826;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: African American.
CC   Doubling time: 48 hours (PubMed=2415247).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gly245Val (c.734G>T); ClinVar=VCV000376603; Zygosity=Homozygous (PubMed=2263646; Cosmic-CLP; DepMap).
CC   Omics: CRISPR phenotypic screen.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Genome ancestry: African=93.38%; Native American=0%; East Asian, North=0.25%; East Asian, South=0%; South Asian=0%; European, North=1.6%; European, South=4.77% (PubMed=30894373).
CC   Derived from site: In situ; Esophagus; UBERON=UBERON_0001043.
ST   Source(s): Cosmic-CLP
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 12
ST   D16S539: 9
ST   D5S818: 10
ST   D7S820: 8,11
ST   TH01: 8
ST   TPOX: 7,8
ST   vWA: 16,20
DI   NCIt; C4024; Esophageal squamous cell carcinoma
DI   ORDO; Orphanet_99977; Squamous cell carcinoma of the esophagus
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_5138 ! HCE-7
SX   Female
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 35
//
RX   PubMed=2263646; DOI=10.1073/pnas.87.24.9958;
RA   Hollstein M.C., Metcalf R.A., Welsh J.A., Montesano R., Harris C.C.;
RT   "Frequent mutation of the p53 gene in human esophageal cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:9958-9961(1990).
//
RX   PubMed=2302677; DOI=10.1016/0165-4608(90)90073-j;
RA   Whang-Peng J., Banks-Schlegel S.P., Lee E.C.;
RT   "Cytogenetic studies of esophageal carcinoma cell lines.";
RL   Cancer Genet. Cytogenet. 45:101-120(1990).
//
RX   PubMed=2415247;
RA   Banks-Schlegel S.P., Quintero J.;
RT   "Growth and differentiation of human esophageal carcinoma cell
RT   lines.";
RL   Cancer Res. 46:250-258(1986).
//
RX   PubMed=2420787; DOI=10.1016/S0021-9258(17)38506-X;
RA   Banks-Schlegel S.P., Quintero J.;
RT   "Human esophageal carcinoma cells have fewer, but higher affinity
RT   epidermal growth factor receptors.";
RL   J. Biol. Chem. 261:4359-4362(1986).
//
RX   PubMed=7972006; DOI=10.1073/pnas.91.23.11045;
RA   Okamoto A., Demetrick D.J., Spillare E.A., Hagiwara K., Hussain S.P.,
RA   Bennett W.P., Forrester K., Gerwin B.I., Serrano M., Beach D.H.,
RA   Harris C.C.;
RT   "Mutations and altered expression of p16INK4 in human cancer.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:11045-11049(1994).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=30971826; DOI=10.1038/s41586-019-1103-9;
RA   Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M.,
RA   Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R.,
RA   Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P.,
RA   van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L.,
RA   Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.;
RT   "Prioritization of cancer therapeutic targets using CRISPR-Cas9
RT   screens.";
RL   Nature 568:511-516(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//